WO2014175690A1 - 자가 절단 카세트를 포함하는 단백질 정제방법 및 이의 용도 - Google Patents
자가 절단 카세트를 포함하는 단백질 정제방법 및 이의 용도 Download PDFInfo
- Publication number
- WO2014175690A1 WO2014175690A1 PCT/KR2014/003639 KR2014003639W WO2014175690A1 WO 2014175690 A1 WO2014175690 A1 WO 2014175690A1 KR 2014003639 W KR2014003639 W KR 2014003639W WO 2014175690 A1 WO2014175690 A1 WO 2014175690A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- tag
- linker
- fusion protein
- self
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/2207—Sortase A (3.4.22.70)
Definitions
- the present invention provides a self-cleaving fusion protein comprising amino acid sequence of interest protein, peptide consisting of amino acid sequence of LPXTG, solutease A cleavage functional domain and tag, nucleic acid encoding the same, expression vector comprising nucleic acid of the present invention, And it relates to a cell transformed with the expression vector of the present invention.
- the present invention relates to a method for purifying a target protein comprising culturing the lysed and purified the transformed cells, and a method for producing a therapeutic antibody-drug conjugate using the method.
- the desired protein required by humans can be produced by expressing the desired protein by culturing cells transformed with the vector expressing it.
- such proteins may be expressed in eukaryotic cells, prokaryotic cells, and the like, and in particular cases, in transformed plants or transformed animals.
- a method of expressing in a transgenic animal that secretes milk, obtaining a target protein through the transgenic animal's milk, and the like have been attempted.
- the desired protein can be isolated and purified from cell culture or milk.
- the method of using a tag for purification is one of very high efficiency among various protein purification techniques, and the tag used is largely divided into a peptide tag and a protein tag.
- Peptide tags are composed of short amino acids, typically his-tag (his-tag, histidine-tag), and especially hexahistidine tag (Hishistidine tag, His6-tag) are used. Histidine peptides have a specific chemical affinity with nickel, so that the fusion protein containing the tag can be purified to high purity by a column containing nickel.
- the protein tag is a tag including the corresponding domain and the like in order to use the features of the domain of the protein binding to a specific component.
- GST-tag Glutathione S-transferase-tag
- GST tags can be purified with high purity by a column with glutathione fixation medium, which is a substrate of GST.
- the tag fusion-expressed to the target protein for protein purification as described above has a risk that it may interfere with the structure or function of the target protein itself, and a method for obtaining the target protein from which the tag is cut has been devised.
- the conventional method required a process of first obtaining a protein including a tag, cutting the tag, and purifying only the target protein again. During this process the desired protein was lost and the amount of protein finally obtained was reduced, and the cost and time for that process was excessive.
- the advantages of the protein purification method using the tag but the method of minimizing the loss of the target protein in the tag cutting process and a method that can be purified protein in a short time.
- Existing protein purification method using Soltease A is to prepare a recombinant expression vector containing a polynucleotide encoding the tag-sortase A (60 ⁇ 206 AA) -LPXTG-target protein to express the protein in the host cell, the host Binding the cell lysate to a tag binding column; Removing impurities; Injecting and reacting a solution comprising calcium and / or triglycine; By obtaining the protein, it is possible to purify the protein and remove the tag at once by using a single column.
- the conventional method using such a Soltease A cleavage functional domain has a problem of low purification efficiency depending on the target protein.
- the present invention completes the present invention by confirming that a higher protein yield than the conventional method can be obtained by applying a linker between the aromatic composition to bind the Soltaze A cleavage functional domain and the Soltaze A and the cleavage sequence. It was.
- Another object of the present invention to provide a cell transformed with the expression vector.
- FIG. 1 is a structural diagram (I) of an existing fusion protein in which the target protein is present at the carboxyl terminus, and a structural diagram (II to IV) of the fusion protein of the present invention in which the target protein is present at the amino terminus and the linker is varied in length. .
- FIG. 2 is a structural diagram of a fusion protein with added (I) or helical linker (II) added for optimization of the peptide linker.
- FIG. 3 is a structural diagram of a fusion protein with the addition of a charge linker (CH linker or AH linker) for optimization of the peptide linker.
- CH linker or AH linker charge linker
- Figure 4 is a structural diagram of the length of the linker, whether the linker is added, the fusion protein with different tags.
- FIG. 5 is a diagram illustrating a purification method using a conventional Soltaze A self-cutting cassette.
- Figure 6 is a diagram stained with Coomassie blue SDS-PAGE gel to confirm the expression of the fusion protein when the expression vector in various types.
- FIG. 7 is a view confirming the expression of the protein (A) and the purification of the cleaved target protein (anti-Myc) (5, 6 lanes of B) when using the conventional purification method using the Soltaze A self-cutting cassette.
- FIG. 8 is a diagram illustrating a purification method using the Soltaise A self-cutting cassette according to the present invention.
- FIG. 9 shows expression vectors containing the Soltaze A autologous cleavage cassette of the present invention and varying in linker length (7, 18, 20 AA) to various E. coli host cells (Origami2 (DE3), and BL21 (DE3)). It is a diagram confirming the expression level of the fusion protein by transformation.
- LB laoding sample
- CP purified protein
- FIG. 11 is a diagram comparing yields of cleaved proteins by varying the presence and concentration of calcium and triglycine in order to optimize the cleavage-buffer.
- FIG. 12 is a diagram confirming the expression and binding degree of the fusion protein when the spiral linker is added.
- FIG. 13 shows 7 A.A between the Soltaize A cleavage functional domain and the tag.
- FIG. It is a diagram confirming the expression and binding degree of the fusion protein in the case of adding a flexible linker (2-1 or 2-2) and not (1).
- FIG. 14 is a diagram confirming the expression, binding and purification degree of the fusion protein to which the charge linker (CH linker or AH linker) is added.
- fusion protein comprising a conventional Soltaze A cleavage cassette, ie, a fusion protein (C-terminal) comprising a target protein at the carboxyl terminus and a fusion protein comprising a Soltaze A cleavage cassette of the present invention, ie, a target protein. It is a diagram confirming the expression, binding and purification degree of the fusion protein (N-terminal) included in the amino terminal.
- 16 is a diagram analyzing the concentration (A) and reaction time (B) of the triglycine-biotin conjugate in order to establish the optimum conditions for conjugation of the drug to the protein of interest.
- ADC therapeutic antibody-drug conjugate
- a self-cleaving fusion protein comprising a target protein, a peptide consisting of an amino acid sequence of LPXTG, a Soltase A cleavage functional domain and a tag.
- the self-cleaving fusion protein of the invention may preferably comprise a peptide linker further between the peptide consisting of the LPXTG amino acid sequence and the Soltease A cleavage functional domain.
- target protein refers to any protein that needs to be obtained in high purity or in bulk for a specific purpose, and includes, without limitation, naturally occurring protein, variant protein, or novel recombinant protein.
- the protein of interest may be a protein that is required to be obtained in high purity or in large quantities for industrial, medical, or academic reasons, and preferably may be a recombinant protein for medical or research purposes, more preferably a polymer protein, a sugar protein, It may be selected from the group consisting of cytokines, growth factors, blood products, vaccines, hormones, enzymes and antibodies. Even more preferably, the protein of interest may be all or part of the light or heavy chain of the antibody, most preferably the light chain variable region (V L ) or heavy chain variable region (V H ) of the antibody.
- peptide consisting of the amino acid sequence of LPXTG means a peptide consisting of the amino acid sequence of Leucine-Proline-any amino acid-Threonine-Glycine, which is a protein Recognition sequence of sortase A having a cleavage function.
- Soltease A recognizes the LPXTG sequence and cleaves between threonine and glycine, thus splitting into a portion containing LPXT and a portion containing G.
- X in the peptide consisting of the amino acid sequence of LPXTG, X may be any amino acid, for example, X may be glutamic acid (E).
- Sportase A is a protein having a function of attaching a surface protein to the cell wall of Gram-positive bacteria, the free carboxyl group and the cell wall of threonine formed by cleaving between threonine and glycine of the LPXTG sequence It is known to play a role of binding free amino groups such as pantaglycin of peptidoglycan.
- Soltase A Soratase A, or Srt A may be mixed with not only whole proteins but also cleavage functional domains of Soltase A.
- Any Solitase A cleavage functional domain can be used in the present invention.
- the corresponding Soltize A may be of bacterial origin, for example derived from Staphylococcus aureus, S. aureus, and more preferably, the Soltize A cleavage functional domain is SEQ ID NO: It may be composed of the amino acid sequence of 8.
- a "tag” is a constant amino acid sequence, peptide, or even a protein domain, which is inserted for the purpose of labeling or obtaining a protein from a recombinant protein, and a method of protein purification using a tag is very high efficiency among protein purification techniques.
- the tag is largely divided into a peptide tag and a protein tag.
- the tag is, for example, polyhistidine tag (polyhistidine tag), GST tag (glutathione-S-transferase tag), HA tag (Hemagglutinin tag), FLAG tag, Myc tag, maltose binding protein tag (maltose binding protein tag ), Chitin binding protein tag and fluorescent tag
- polyhistidine tag polyhistidine tag
- GST tag glutthione-S-transferase tag
- HA tag Hemagglutinin tag
- FLAG tag Myc tag
- maltose binding protein tag maltose binding protein tag
- Chitin binding protein tag and fluorescent tag may be selected from the group consisting of, but not limited to, preferably a poly histidine peptide tag, more preferably 6 to 12 histidine It may be a peptide tag, and most preferably it may be a poly histidine peptide tag having 10 histidines.
- the tag serves to attach the entire fusion protein linked thereto to the column that binds the tag. Through this it is possible to obtain the desired protein ultimately included in the fusion protein.
- a "self-cleaving fusion protein” means that a domain having a cleavage function and a recognition sequence recognized by the domain are simultaneously included in a fusion protein, and when a certain condition is reached, the cleavage functional domain is activated to identify a recognition sequence within the same protein. It means a protein that is recognized and cleaved. In the present invention, it may be a fusion protein including a cleavage functional domain derived from Soltaize A and LPXTG recognized by the domain, and may further include other components.
- self-cleaving cassette refers to a domain set including a domain having a cleavage function and a recognition sequence recognized and cleaved by the domain, and preferably, a cleavage functional domain derived from Solteide A and LPXTG recognized by the domain. It may be a domain set including.
- a “peptide linker” in the present invention is a peptide used for physicochemical distance or linkage between domains within a fusion protein.
- the fusion protein of the invention may comprise a linker between Soltaze A and LPXTG peptide.
- Natural linkers, flexible linkers, helical linkers, charge linkers (positive or negatively charged linkers), coiled coil linkers, and the like can be used for this.
- the amino acid of the amino acid sequence is indicated by the amino acid single letter abbreviation used conventionally in the art.
- the flexible linker basically shows the flexible movement because amino acids present in the linker do not repel or accumulate with each other.
- Spiral linker in the present invention may include a general formula of A (EAAK) m A (m is 2 to 5), (H 4 ) 2 linker (LEA (EAAAK) 4 ALEA (EAAAK) 4AL, SEQ ID NO: 50 AA) May be 1).
- the charge linker may be a linker having a positive charge or a negative charge
- the positive charge linker may be a CH linker (TRARLSKELQAAQARLGADMEDVCGRLVQYRG, SEQ ID NO: 2)
- the negative charge linker may be an AH linker (KEQQNAFYEILHLPNLNEEQRNGFIQSLKDDPSQSA).
- Coiled coil linker is a linker having a helical three-dimensional structure and having the ability to bind with other coiled coil domains or linkers and may be one of SEQ ID NOs: 9 to 16 or SEQ ID NOs: 48 to 55.
- the peptide linker may be a flexible linker, and may have an S c (SG 4 ) 1 (GGSSRSS) G d S e form (SEQ ID NO: 4).
- C is 0 to 5
- d is 0 to 5
- e is 0 to 5
- l is 0 to 10 in S c (SG 4 ) 1 (GGSSRSS) G d S e .
- the length of the peptide linker is not important, and the length of the linker may vary depending on the protein of interest for accessibility with the active site, but preferably 19 to 40 amino acids, more preferably 19 to It may be composed of 25 amino acids. Most preferably, it may be a peptide linker consisting of the amino acid sequence of SEQ ID NO: 7.
- linker optimization was performed by varying the length of the linker, the number and type of linkers in order to confirm the effect of the linker on the yield of the target protein.
- the helical linker was inserted between the Soltease A cleavage functional domain and the tag to confirm the effect on the yield of the desired protein (Examples 5-3, Figures 12 and 14). ). Specifically, when the helical linker is inserted between the Soltease A cleavage functional domain and the tag further with the flexible linker (20 AA) between the LPXTG recognition sequence and the Soltease A cleavage functional domain remaining, the fusion protein is It could be confirmed that it is hardly bound to (FIG. 12).
- charge linkers may be used to link the flexible linker (20 AA) between the LPXTG recognition sequence and the Soltaze A cleavage functional domain. Even when inserted between the Soltase A cleavage functional domain and the tag while remaining, it was hardly bound to the column and little cleavage protein was found (FIG. 14).
- the self-cleaving fusion protein of the present invention may be composed of the amino acid sequence of SEQ ID NO: 17 or 18. It includes an antibody variable region as a target protein, and includes an LPETG recognition sequence, a peptide linker, a Soltease A cleavage functional domain (60-206 A.A.), and a column binding tag (His9) sequentially from the amino terminus.
- the present invention provides a nucleic acid comprising a nucleotide sequence encoding a self-cleaving fusion protein of the present invention.
- the nucleotide sequence encoding the fusion protein of the present invention may be a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 17 or 18, preferably, may be the nucleotide sequence of SEQ ID NO: 56 or 57.
- the present invention provides an expression vector comprising the nucleic acid.
- the "expression vector” refers to a vector operably linked to a promoter or the like to express a specific gene in a specific prokaryotic or eukaryotic host cell.
- the backbone of the vector may vary depending on the host cell.
- the backbone may be a vector expressable in E. coli, and more preferably, a pET21b, pLIC, or pET23a vector (Novagen).
- the present invention provides a cell transformed with the expression vector of the present invention.
- the cells to be transformed are also called host cells, and may be eukaryotic or prokaryotic. In the present invention, it may be preferably Escherichia coli, and more preferably E. coli Origami2 (DE3) or E. coli BL21 (DE3).
- the expression vectors of the present invention were transformed and expressed using Origami2 (DE3) or BL21 (DE3) as a host cell (Fig. 9). As can be seen in Figure 9 there was no significant difference in the expression pattern between Origami2 and BL21.
- the present invention provides a method for purifying a target protein comprising culturing the cells of the present invention to obtain cell lysates and purifying the target protein from the cell lysates.
- purifying the protein of interest from the cell lysate comprises injecting the cell lysate into a column that binds to a tag present in the fusion protein; Washing the column; Equilibrating with a cleavage-buffer comprising at least one selected from the group consisting of calcium and triglycine and cleavage reaction; And obtaining the cleavage-buffer from the column to obtain the desired protein from which the tag has been removed.
- “column” is a device that functions to separate and / or purify a specific component, protein, or compound while injecting a mixture solution containing the specific component, protein, or compound, and particularly, in the present invention.
- Compounds, components, proteins, etc., which have the property of binding to a specific tag contained in the protein are fixed in the column to attach, separate, and purify the tagged proteins in the column.
- the tag included in the fusion protein is a histag (tag containing histidine)
- a Ni-NTA column using a nickel binding property may be used.
- the tag included in the fusion protein is GST, glutathione is fixed. Columns can be used.
- cleavage-buffer means a buffer for activating a cleavage functional domain, and in particular, a buffer for activating Saltase A.
- the cleavage-buffer may be one comprising calcium and / or triglycine, preferably at least triglycine.
- the cleavage-buffer may preferably include 0.1 to 10 mM of calcium and 0.1 to 10 mM of triglycine, more preferably 0.2 to 5 mM of calcium and 0.2 to 5 mM of triglycine. .
- the yield of cleaved protein was confirmed by varying the presence or absence of calcium or triglycine and concentration conditions.
- the yield of cleaved protein by the cleavage-buffer in which the concentration of one of calcium and triglycine was fixed at 5 mM and the other was mixed at concentrations of 0, 0.2, 1, 5 mM was compared with the negative control without both.
- therapeutic antibody-drug conjugate is composed of three components including a drug, an antibody and a linker (linker) connecting the antibody and the drug
- the therapeutic antibody-drug Binding technology is a method of delivering drugs to tumor cells using antibodies that specifically bind to specific antigens expressed on the surface of cancer cells.
- the therapeutic antibody-drug conjugates can be prepared using the present invention. Specifically, a self-cleaving cassette including 'antibody-linker-saltase' at the amino terminal, and calcium and / or triglycine must be present in order for Soltaze A to recognize the cleavage sequence (LPXTG) and perform a cleavage function. And the drug is connected to the C-terminus of the derivative triglycine which induces this cleavage.
- GGG-drug which connects drug to triglycine C-terminus
- it is used for cleavage reaction of self-cutting cassette including the constructed 'antibody-linker-saltase' It can be prepared in the form of 'antibody-liker-LPETGGG-drug' by an optimized cleavage reaction.
- the drug that can be used in the therapeutic antibody-drug conjugate of the present invention includes any compound, part or group having a cytotoxic or cytostatic effect,
- a chemotherapeutic agent that can function as a microtubulin inhibitor, mitosis inhibitor, topoisomerase inhibitor, or DNA intercalator;
- micro RNA miRNA
- siRNA siRNA
- shRNA capable of inhibiting the expression of certain oncogenes
- drugs include maytansinoids, auristatins, dolastatins, tricortesenes, CC1065 (cytotoxic compounds), calicheamicins and other enedyne antibiotics, taxanes, anthracyclines, methotrexate, adriamycin, binddesin, vinca Alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin, daunomycin and its stereoisomers, isomers, homologues or derivatives, and other intercalating enzymes And fragments thereof such as nucleolytic enzymes, antibiotics, and toxins (enzymatically active toxins or small molecule toxins of bacterial, fungal, plant or animal origin) and various antitumor such as cisplatin, CPT-11, doxorubicin, paclitaxel and docetaxel Or anticancer agents, and the like,
- the yield of cleavage protein was determined by varying the presence or absence of triglycine-biotin and concentration conditions.
- concentration of triglycine-biotin was mixed at concentrations of 0, 10 nM, 100 nM, 500 nM, 1 ⁇ M, 10 ⁇ M, 100 ⁇ M, 500 ⁇ M, 1 mM to compare target protein yield by cleavage-buffer with the negative control.
- the cleavage-buffer preferably contains 0.1 to 10 mM of calcium, and triglycine-drug (GGG-drug) is preferably reacted, including 500 nM to 1 mM, but is not limited thereto.
- the time for conjugating the wood protein and triglycine-drug (GGG-drug) is preferably 4 to 16 hours, but is not limited thereto.
- the target protein is preferably an antibody against cancer cell surface antigens, but is not limited thereto.
- composition of PCR reaction solution and PCR execution conditions for obtaining various genes used in the present invention and preparing a vector are as follows.
- the PCR reaction solution was 5 ⁇ l of 2.5 mM dNTP mix, 10 ⁇ l of 5X PrimeSTAR buffer, 1 ⁇ l of 100 ⁇ M forward and reverse primers, 1 ⁇ l of 100 ng / uL template DNA, 0.5 ⁇ l of 2.5U / uL PrimeSTAR polymerase, and distilled water. A total of 50 ⁇ l was prepared, including 31.5 ⁇ l.
- the prepared PCR reaction solution was subjected to a two-step PCR of 29 cycles of 10 seconds at 98 ° C and 1 minute at 68 ° C. PCR completed samples were stored at 4 °C.
- primer 1_sfi (5'-ccgtg gcc cag gcg gcc GCA AGC AGC GGC CTG AAC GAC ATC TTC GAG GCC-3 ': SEQ ID NO: 19) or primer 1 (5'-ATGT CAT ATG GCA AGC AGC GGC CTG AAC GAC ATC Biotin acceptor peptide using TTC GAG GCC-3 ': SEQ ID NO: 20), and primer 2 (5'-CTG CAT TTC GTG CCA CTC GAT CTT CTG GGC CTC GAA GAT GTC GTT-3': SEQ ID NO: 21) DNA sequence encoding a) was amplified by PCR.
- Primer 3 (5'-ATC GAG TGG CAC GAA ATG CAG GCT AAG CCG CAG ATT CCG-3 ': SEQ ID NO: 22) and Primer 4 (5'-GCC GGT CTC GGG AAG CTT CTT GAC CTC GGT AGC GAC AAA-3' : DNA sequence encoding the 60-206th amino acid sequence of SrtA (GenBank Accession No. AF162687) derived from Staphylococcus aureus (S.aureus ) was amplified by PCR using SEQ ID NO: 23).
- Primer 5 (5'-CAG TAA GCT TCC CGA GAC CGG CGA TAT CCA GAT GAC TCA GAGC-3 ': SEQ ID NO: 24)
- Primer 6 (5'-ACT CGA ACC CGC CGT ACG TTT TAT CTC TAC CTT TGT-3' : Secondary DNA sequence encoding LPETG-target (VL) was amplified by PCR using SEQ ID NO: 25) and template target (VL).
- the resulting DNA fragment was cleaved with NdeI and NotI , ligated into a pET23a vector (Novagen) that induces expression of the target protein into the cytoplasm, and cleaved with SfiI, followed by the fusion protein BAP-sortase-LPETG-target-myc (Fig. I) of 1) was ligated with pCom3x, a vector that induces expression into periplasm.
- primer 8 (5'-ATG TCA TAT GGA CAT TCA GAT GAC ACA GAGT-3 ': SEQ ID NO: 27) and primer 9 (5'-ggaaccaccgccggtctcgggaag AAG ATC TTC TTC ACT AAT TAAC-3': SEQ ID NO: 28)
- DNA sequence encoding the target-LPETG-linker (7 AA) to which the linker (7 AA) (GGSSRSS: SEQ ID NO: 5) was linked was amplified by PCR.
- Primer 8 and Primer 10 (5'-GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC GCC ACC GGA TGA GCC GGT CTC GGG AAG AAG AT-3 ': SEQ ID NO: 29) and the PCR product target-LPETG
- the DNA sequence encoding the target-LPETG-linker (18 AA) to which the linker (18 AA) (SSGGGGSGGGGGGSSRSS: SEQ ID NO: 6) was linked was amplified by PCR using a linker (7 AA).
- Primer 11 (5'-gag acc ggc ggt ggt tcc tct aga tct tcc cag gct aag ccg cag att-3 ': SEQ ID NO: 30) and primer 12 (5'-taat GC GGC CGC tta atgatggtg ATG GTG ATG ATG ATG ATGGC- 3 ': SEQ ID NO: 31) was used to amplify the DNA sequence encoding the linker (7 AA) -SrtA (60-206) by PCR.
- Linker (20 AA) (SSGGGGSGGGGGGSSRSSGS: SEQ ID NO: 7) linked using primer 15 (5'-GGT TCC TCT AGA TCT TCC GGA AGC cag gct aag ccg cag att-3 ': SEQ ID NO: 34) and primer 14 DNA sequences encoding 20 AA) -SrtA (60-206) were amplified by PCR.
- Primer 15, Primer 16 (5'-ATG ATG ATG GCG AGA GCT ACG GCT GCT GCC GCC CTT GAC CTC GGT AGC GAC AAA GA-3 ': SEQ ID NO: 35) and Primer 17 (5'-TAA TGC GGC CGC TTA ATG ATG Linker (20 AA) (SSGGGGSGGGGGGSSRSSGS: SEQ ID NO: 7) is linked to the N terminus using GTG ATG GTG ATG ATG ATG ATG GCG AGA GCT ACG GCT-3 ': SEQ ID NO: 36 and linker (7 AA) (GGSSRSS: sequence DNA sequence encoding linker (20 AA) -SrtA (60-206) -linker (7 AA) linked to No. 5) at the C terminus was amplified by PCR.
- GGSSRSS sequence DNA sequence encoding linker (20 AA) -SrtA (60-206) -linker (7 AA) linked to No. 5
- the linker (20 AA) (SSGGGGSGGGGGGSSRSSGS: SEQ ID NO: 7) was added to the N terminus by PCR using primer 15 and primer 20 (5'-GTG CCC GCG TCT TGA CCT CGG TAG CGA CAA AGA TCTT-3 ': SEQ ID NO: 39). Amplify the DNA sequence linked and encoding the TRA- of the N terminus of the CH linker (32 AA) and primer 21 (5'- GCT GTC CAA GGA GCT GCA GGC GGC GCA GGC CCG GCT GGG CGC GGA CAT G-3 ': sequence No.
- primer 22 (5'-GCG GTA CTG CAC CAG GCG GCC GCA CAC GTC CTC CAT GTC CGC GCC CAG CCGG-3 ': SEQ ID NO: 41) and primer 23 (5'-GAG GTC AAG ACG CGG GCA CGG CTG TCC AAG GAG CTG CAG-3 ': SEQ ID NO: 42) and Primer 24 (5'-TAA T GC GGC CGC TTA ATG ATG CTG ATG GTG ATG GCC GCG GTA CTG CAC CAG GC-3': SEQ ID NO: 43) Amplify the CH linker moiety and linker (20 AA) -SrtA (20 AA) (SSGGGGSGGGGGGSSRSSGS: SEQ ID NO: 7) linked to the N terminus and CHL linker (32 AA) (TRARLSKELQAAQARLGADMEDVCGRLVQYRG: SEQ ID NO: 2) linked to the C terminus 60 DNA sequences encoding CHL linker (32
- Linker 20 AA (SSGGGGSGGGGGGSSRSSGS: SEQ ID NO: 11) is linked to the N terminus using Primer 15 and Primer 25 (5'-CGG ATC ACC CTT GAC CTC GGT AGC GAC AAA GAT CTT-3 ': SEQ ID NO: 44) Amplify the DNA sequence encoding the KEQ- of the N terminus of the AH linker (45 AA) and primer 27 (5'- GAG GTC AAG GGT GAT CCG AAA GCT GAC AAC AAA TTC-3 ': SEQ ID NO: 45) and primer 27 ( 5'-GTG ATG ATG ATG GTG AGC TTT TGG TGC TTG TGC ATC AT-3 ': SEQ ID NO: 46) was used to amplify the AH linker using the pIG20 vector as a template.
- AH linker (45 AA) (KEQQNAFYEILHLPNLNEEQRNGFIQSLKDDPSQSAN LLAEAKKL: SEQ ID NO: 3) is a DNA sequence encoding a linker (20 AA) -SrtA (60-206) -AHL linker (45 AA) linked to the C terminus.
- target (VL) -LPETG-linker (7 AA) -Sortase-H9 (II in FIG. 1) was prepared by primer 8, primer 12 and the PCR product (target-LPETG-linker (7 AA) and linker (7 AA). It was amplified by overlapping PCR using a mixture of) -SrtA).
- the gene encoding target (VL) -LPETG-linker (18 AA) -Sortase-H9 (III in FIG. 1) was prepared by primer 8, primer 14 and the PCR product (target-LPETG-linker (18 AA) and linker (18). It was amplified by overlapping PCR using a mixture of AA) -SrtA).
- the gene encoding target (VL) -LPETG-linker (20 AA) -Sortase-H9 (IV in FIG. 1) was prepared by primer 8, primer 14 and the PCR product (target-LPETG-linker (20 AA) and linker (20). It was amplified by overlapping PCR using a mixture of AA) -SrtA).
- the gene encoding target (VL) -LPETG-linker (20 AA) -Sortase-linker (7 AA) -H9 was selected from primer 8, primer 17 and the PCR product (target-LPETG-linker (20). Amplification by overlapping PCR using a mixture of AA) and linker (20 AA) -SrtA-linker (7 AA)).
- the gene encoding target (VL) -LPETG-linker (20 AA) -Sortase- (H4) 2L linker (50 AA) -H9 (II of FIG. 2) was selected from primer 8, primer 19 and the PCR product (target-LPETG). Amplification by overlapping PCR using a mixture of linker (20 AA) and linker (20 AA) -SrtA- (H4) 2L linker (50 AA)).
- the gene encoding target (VL) -LPETG-linker (20 AA) -Sortase-CHL linker (32 AA) -H9 (I of FIG. 3) was selected from primer 8, primer 24 and the PCR product (target-LPETG-linker ( Amplification by overlapping PCR using a mixture of 20 AA) and a linker (20 AA) -SrtA-CHL linker (32 AA).
- the gene encoding target (VL) -LPETG-linker (20 AA) -Sortase-AHL linker (45 AA) -H9 (II of FIG. 3) was selected from primer 8, primer 28 and the PCR product (target-LPETG-linker ( Amplification by overlapping PCR using a mixture of 20 AA) and a linker (20 AA) -SrtA-AHL linker (45 AA)).
- the resulting DNA fragment is cleaved with NdeI and NotI and the fusion proteins target-LPETG-other linker-Sortase-R9, target-LPETG-other linker-Sortase-H6, or target-LPETG-other linker-Sortase-H9 It was ligated with the pET23a vector (Novagen) which is the expressing vector.
- the fusion proteins target-LPETG-different linker-Sortase-R9, target-LPETG-different linker-Sortase-H6, or target-LPETG-different linker-Sortase-H9 are the target and LPETG-different linker-Sortase-R9, LPETG- There is a HindIII site between sequences encoding another linker-Sortase-H6, or LPETG-other linker-Sortase-H9.
- the supernatant of the lysate was loaded into 5 ml Ni-NTA (GE) column and with 20-fold column volume buffer A (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 30 mM imidazole, and 5 mM BME). After washing, washed with 5-fold column volume of buffer B (50 mM Tris-Cl, pH 8.0, 150 mM NaCl). After washing, aliquote of protein-bound resin was equilibrated with cleavage buffer (Buffer B containing 5 mM CaCl 2 and 5 mM tri-Gly), and then reacted at 25 ° C. for 1 hour.
- buffer A 50 mM Tris-Cl, pH 8.0, 150 mM NaCl
- buffer B 50 mM Tris-Cl, pH 8.0, 150 mM NaCl
- cleavage buffer Buffer B containing 5 mM CaCl 2 and 5 mM tri-Gly
- FIGS. 5 and 8 show a process for purifying a fusion protein in which Sortase A is bound to the existing C terminus of I of FIG. 1
- FIG. 8 shows a process for purifying a fusion protein in which Sortase A is bound to the N-terminal of the present invention. Giving.
- Protein purity was analyzed by Coomassie blue staining SDS-PAGE gel. In addition, the expression and purification of some samples were confirmed by Western blotting.
- Example 2 Expression from the cell lysate obtained by Example 2 from host cells (E. coli, E. coli ) transformed with expression vectors obtained by inserting the fusion proteins corresponding to I of FIG. 1 into pET21b, pET23a, and pLIC It was confirmed. This was purified by binding to the Ni-NTA (GE) column through Example 3, and confirmed the protein bound to the column.
- host cells E. coli, E. coli
- the expression and purification were confirmed by Western blotting using Coomassie blue staining and Myc tag bound to the target protein.
- the fusion protein purification efficiency was compared when the position of the target protein is different from the N terminal and the C terminal. This was confirmed through the experiment according to Example 2 and Example 3.
- Example 2dml For cells obtained through the above Example 2dml method by transforming the vector expressing the fusion proteins corresponding to II to IV of Figure 1 in Origami2 (DE3) or BL21 (DE3) and incubated in LB, SB or dYT medium The expression was confirmed in the seafood. This was purified by binding to a Ni_NTA (GE) column as disclosed in Example 3, and confirmed the protein bound to the column.
- GE Ni_NTA
- the expression and purification were confirmed by coomassie blue staining and the target protein was Western blotting using HA tag antibody in the case of V H , myc tag antibody in the case of V L.
- linker 7 A.A.
- Linker (GGSSRSS, SEQ ID NO: 5), and 18 A.A.
- the linker SSGGGGSGGGGGGSSRSS, SEQ ID NO: 6
- the weak tag protein CP lane, cleaved protein lane, 15 kDa position
- 20 A.A In the linker (SSGGGGSGGGGGGSSRSSGS, SEQ ID NO: 7) it can be seen that a large amount of the detagged protein is obtained.
- the linker When the linker is present in the C-terminal part as well as the N-terminal part of the Sortase A domain, it was compared using a fusion protein in which a linker was additionally inserted between the Sortase A domain and the His tag.
- the difference between (1) and (2) is the difference between presence or absence of linker (7 A.A., GGSSRSS) after Sotase A. Expression of the two fusion proteins and the degree of column binding were confirmed by coomassie blue staining.
- the linker consisting of a large number of glycine and serine and one arginine was replaced with various kinds of linkers that can reduce interference between domains, thereby confirming column binding or yield.
- the binding rate was confirmed by expressing the fusion protein having the structure of I and II of FIG. 2 using AA, SEQ ID NO: 1).
- the fusion protein is overexpressed, but it can be seen that hardly binds to the column. It was confirmed that the helical linker used in the fusion protein did not have an effect of increasing the binding rate.
- Soltase A requires calcium and / or triglycine for the cleavage function to recognize the cleavage sequence (LPXTG).
- LPXTG cleavage sequence
- the negative control group was not able to observe the cleaved protein at all (about 15 kDa), when either of the cleavage protein was observed.
- the amount of cleaved protein obtained when the concentration of calcium to 5 to 5 mM and triglycine was adjusted to 0 to 5 mM showed little difference, whereas the concentration of triglycine to 5 to 5 was included.
- Fig. 11B When adjusted to mM it can be seen that less cleaved protein is obtained when the triglycine is not included (Fig. 11B). However, once triglycine entered, there was little difference in the amount of cleaved protein obtained.
- triglycine contained in the cleavage-buffer plays an important role in the cleavage function of the solutes, and the difference in concentration does not mean much.
- the optimal concentration condition of triglycine required for efficient drug conjugation was established.
- Bioglycine with triglycine-fused biotin was used, and the concentration was 0, 10 nM, 100 nM, 500 nM, 1 ⁇ M, 10 ⁇ M, 100 ⁇ M, 500 ⁇ M, and 1 mM, respectively.
- the conjugation of the target protein with biotin was compared with the negative control.
- Negative control was used three conditions (1: 50mM Tris buffer, pH8.0 / 2: 50mM Tris buffer, pH8.0 + 500 ⁇ M triglycine-biotin / 3: reaction buffer).
- the target protein-biotin conjugation was confirmed by Western blot using the Myc tag bound to the target protein and the total concentration of the target protein.
- the streptavidin was used to confirm the conjugation reaction between the target protein and biotin.
- Optimal reaction time conditions were analyzed using the concentration of triglycine-biotin established in Example 7-1.
- the concentration of the target protein was fixed at two concentrations of 500 ⁇ M and 1 mM, and the reaction time was 0, 30 minutes, 1, 2, 3, 4, 6 hours and 16 hours, and then the conjugate of the target protein and biotin was negatively controlled. Compared.
- the fusion protein having the structure of the target protein-LPETG-linker (20 AA) -Sortase-tag has a very high yield with excellent column binding ability and excellent Sortase A self-cleaving activity. It can be seen that the therapeutic antibody-drug conjugate used was prepared.
- the present invention relates to a self-cleaving fusion protein comprising a self-cleaving cassette consisting of a peptide consisting of the amino acid sequence of LPXTG, which is a recognition sequence thereof, and a Soltease A cleavage functional domain, and furthermore, a process for purifying and removing a tag of interest.
- This is very useful in that it can be completed in one purification process.
- the position of the target protein at the amino terminus enhances the column binding ability and the self-cleaving ability of the fusion protein, the high purity of the tagged protein can be obtained, and the purification and tag removal process through the cut-buffer.
- This one-step process is widely used in various fields that require high purity and large amount of protein in that the time and effort required for purification is drastically reduced, and in one step, the loss of obtained protein is reduced.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (33)
- (i) 목적 단백질;(ii) 서열식 I의 펩타이드;(iii) 솔테이즈 A(Sortase A) 절단 기능 도메인; 및(iv) 태그를 포함하는 융합 단백질로서, 상기 (i) 내지 (iv)는 융합 단백질의 아미노 말단으로부터 카복실 말단 순서로 존재하는 것인 융합 단백질:서열식 IL-P-X-T-G상기 서열식 I에서 L은 류신(Leucine)이고, P는 프롤린(Proline)이며, X는임의의 아미노산이고, T는 트레오닌(Threonine)이며, G는 글리신(Glycine)인 것이다.
- 제1항에 있어서, 상기 자가 절단 융합 단백질은 추가로 LPXTG 아미노산 서열로 이루어지는 펩타이드와 솔테이즈 A 절단 기능 도메인 사이에 펩타이드 링커를 포함하는 것인, 자가 절단 융합 단백질.
- 제1항에 있어서, 상기 X는 글루탐산(Glutamic Acid)인 것인, 자가 절단 융합 단백질.
- 제2항에 있어서, 상기 펩타이드 링커는 천연 링커, 가요성 링커(flexiblelinker), 나선형 링커(helical linker), 양전하성 링커, 음전하성 링커, 및 coiled coil 링커로 이루어진 군으로부터 선택되는 것인, 자가 절단 융합 단백질.
- 제2항에 있어서, 상기 펩타이드 링커는 Sa(SG4)n(GGSSRSS)GbSc의 아미노산 서열로 이루어진 것으로, 상기 Sa(SG4)n(GGSSRSS)GbSc의 아미노산 서열에서 S는 세린(Serine), G는 글라이신(Glycine), R은 알기닌(Arginine)이고, a는 0 내지 5이고, b는 0 내지 5 이며, c는 0 내지 5이고, n은 0 내지 10인 것인, 자가 절단 융합 단백질.
- 제2항에 있어서, 상기 펩타이드 링커는 19개 내지 40개 아미노산으로 이루어진 것인 자가 절단 융합 단백질.
- 제6항에 있어서, 상기 펩타이드 링커는 19개 내지 25개 아미노산으로 이루어진 것인 자가 절단 융합 단백질.
- 제2항에 있어서, 상기 펩타이드 링커는 서열번호 7인 아미노산 서열로 구성되는 것인 자가 절단 융합 단백질.
- 제1항에 있어서, 상기 솔테이즈 A는 스타필로코커스 아우레우스(Staphylococcus aureus, S.aureus) 유래 솔테이즈 A인 것인 자가 절단 융합 단백질.
- 제1항에 있어서, 상기 솔테이즈 A는 서열번호 8인 아미노산 서열로 구성되는 것인 자가 절단 융합 단백질.
- 제1항에 있어서, 상기 태그는 폴리 히스티딘 태그(poly-histidine tag), GST 태그(glutathione-S-transferase tag), HA 태그(Hemagglutinin tag), FLAG 태그, Myc 태그, 말토오스 결합 단백질 태그(maltose binding protein tag), 키틴 결합 단백질 태그(Chitin binding protein tag) 및 형광 태그로 이루어진 군 중에서 선택된 것인 자가 절단 융합 단백질.
- 제11항에 있어서, 상기 태그는 폴리 히스티딘 태그인 것인 자가 절단 융합 단백질.
- 제12항에 있어서, 상기 폴리 히스티딘 태그는 연속된 히스티딘 6 내지 12개 아미노산으로 이루어진 것인 자가 절단 융합 단백질.
- 제1항에 있어서, 상기 목적 단백질은 고분자 단백질, 당 단백질, 사이토카인, 성장인자, 혈액제제, 백신, 호르몬, 효소 및 항체로 이루어진 군에서 선택된 것인, 자가 절단 융합 단백질.
- 제1항에 있어서, 상기 목적 단백질은 항체의 경쇄 또는 중쇄의 전부 또는 일부분인 것인 자가 절단 융합 단백질.
- 제15항에 있어서, 상기 목적 단백질은 항체의 경쇄 가변영역 또는 중쇄 가변 영역인 것인 자가 절단 융합 단백질.
- 제1항에 있어서, 상기 자가 절단 융합 단백질은 서열번호 17 또는 18인 아미노산 서열로 구성되는 것인 자가 절단 융합 단백질.
- 제1항 내지 제17항의 융합 단백질을 코딩하는 뉴클레오티드 서열을 포함하는 핵산.
- 제18항의 핵산을 포함하는 발현벡터.
- 제19항의 발현벡터로 형질전환된 세포.
- 제20항에 있어서, 상기 세포는 진핵 세포 또는 원핵 세포인 것인 형질전환된 세포.
- 제21항에 있어서, 상기 세포는 대장균(Escherichia coli)인 것인 형질전환된 세포.
- 제22항에 있어서, 상기 대장균은 Origami2(DE3) 또는 BL21(DE3)인 것인 형질전환된 세포
- (1) 제20항의 세포를 배양하여 세포 용해물을 얻는 단계;(2) 세포 용해물로부터 목적 단백질을 정제하는 단계를 포함하는 목적 단백질의 정제방법.
- 제24항에 있어서, 상기 (2) 정제하는 단계는,(a) 세포 용해물을 융합 단백질에 존재하는 태그와 결합하는 컬럼에 주입하는 단계;(b) 컬럼을 세척하는 단계;(c) 칼슘 및 트리글라이신으로 이루어진 군 중에서 선택된 하나 이상을 포함하는 절단-버퍼로 평형화시키고 절단 반응시키는 단계;(d) 절단-버퍼를 수득하여 태그가 제거된 목적 단백질을 수득하는 단계로 이루어진 목적 단백질의 정제방법.
- 제25항에 있어서, 상기 (c) 단계에서 절단-버퍼는 적어도 트리글라이신을 포함하는 것인 목적 단백질의 정제방법.
- 제25항에 있어서, 상기 (c) 단계에서 절단-버퍼는 칼슘 0.1 내지 10 mM 및 트리글라이신 0.1 내지 10 mM을 포함하는 것인 목적 단백질의 정제방법.
- 제27항에 있어서, 상기 (c) 단계에서 절단-버퍼는 칼슘 0.2 내지 5 mM 및 트리글라이신 0.2 내지 5 mM을 포함하는 것인 목적 단백질의 정제방법.
- (1) 제1항의 융합 단백질과 트리글라이신-약물(GGG-drug)을 칼슘을 포함하는 절단-버퍼 내에서 반응시켜 목적 단백질에 트리글라이신-약물(GGG-drug)을 접합시키는 단계;(2) 절단-버퍼를 수득하여 태그가 제거된 목적 단백질과 트리글라이신-약물(GGG-drug) 접합체를 수득하는 단계를 포함하는 치료용항체-약물 결합체의 제조방법.
- 제29항에 있어서, 상기 (1) 단계에서 절단-버퍼는 칼슘 0.1 내지 10 mM을 포함하는 것인 치료용항체-약물 결합체의 제조방법.
- 제29항에 있어서, 상기 (1) 단계에서 트리글라이신-약물(GGG-drug)을 500 nM 내지 1 mM을 포함하는 것인 치료용항체-약물 결합체의 제조방법.
- 제29항에 있어서, 상기 (1) 단계에서 접합시키는 시간은 3 내지 16 시간인 것을 특징으로하는 치료용항체-약물 결합체의 제조방법.
- 제29항에 있어서, 상기 목적 단백질은 암세포 표면 항원에 대한 항체인 것을 특징으로 하는 치료용항체-약물 결합체의 제조방법.
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480033267.9A CN105339391B (zh) | 2013-04-25 | 2014-04-25 | 包括自切割盒的蛋白质的精制方法及其应用 |
US14/785,881 US10077299B2 (en) | 2013-04-25 | 2014-04-25 | Method for refining protein including self-cutting cassette and use thereof |
SG11201508732PA SG11201508732PA (en) | 2013-04-25 | 2014-04-25 | Method for refining protein including self-cutting cassette and use thereof |
EP14787873.0A EP2990423B1 (en) | 2013-04-25 | 2014-04-25 | Method for refining protein including self-cutting cassette and use thereof |
CA2909513A CA2909513C (en) | 2013-04-25 | 2014-04-25 | Method for refining protein including self-cutting cassette and use thereof |
KR1020157030691A KR101808223B1 (ko) | 2013-04-25 | 2014-04-25 | 자가 절단 카세트를 포함하는 단백질 정제 방법 및 이의 용도 |
AU2014258109A AU2014258109B2 (en) | 2013-04-25 | 2014-04-25 | Method for refining protein including self-cutting cassette and use thereof |
NZ713602A NZ713602A (en) | 2013-04-25 | 2014-04-25 | Method for refining protein including self-cutting cassette and use thereof |
JP2016510621A JP6176392B2 (ja) | 2013-04-25 | 2014-04-25 | 自己切断カセットを含むタンパク質精製方法及びこれの用途 |
RU2015150335A RU2639527C2 (ru) | 2013-04-25 | 2014-04-25 | Способ очистки белка, включенного в саморасщепляющуюся кассету, и его применение |
IL242147A IL242147B (en) | 2013-04-25 | 2015-10-18 | Method for refining protein including self-cutting cassette and use thereof |
US16/100,080 US20190077846A1 (en) | 2013-04-25 | 2018-08-09 | Method for refining protein including self-cutting cassette and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130046322 | 2013-04-25 | ||
KR10-2013-0046322 | 2013-04-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/785,881 A-371-Of-International US10077299B2 (en) | 2013-04-25 | 2014-04-25 | Method for refining protein including self-cutting cassette and use thereof |
US16/100,080 Division US20190077846A1 (en) | 2013-04-25 | 2018-08-09 | Method for refining protein including self-cutting cassette and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014175690A1 true WO2014175690A1 (ko) | 2014-10-30 |
Family
ID=51792155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/003639 WO2014175690A1 (ko) | 2013-04-25 | 2014-04-25 | 자가 절단 카세트를 포함하는 단백질 정제방법 및 이의 용도 |
Country Status (12)
Country | Link |
---|---|
US (2) | US10077299B2 (ko) |
EP (1) | EP2990423B1 (ko) |
JP (1) | JP6176392B2 (ko) |
KR (1) | KR101808223B1 (ko) |
CN (1) | CN105339391B (ko) |
AU (1) | AU2014258109B2 (ko) |
CA (1) | CA2909513C (ko) |
IL (1) | IL242147B (ko) |
NZ (1) | NZ713602A (ko) |
RU (1) | RU2639527C2 (ko) |
SG (1) | SG11201508732PA (ko) |
WO (1) | WO2014175690A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109072212A (zh) * | 2016-03-30 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 改善的分选酶 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
JP6895953B2 (ja) | 2015-09-25 | 2021-06-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ソルターゼaを利用してチオエステルを作製するための方法 |
JP6998863B2 (ja) | 2015-09-25 | 2022-02-04 | エフ.ホフマン-ラ ロシュ アーゲー | 深共融溶媒におけるソルターゼaを利用したアミド基転移 |
EP3353291B1 (en) | 2015-09-25 | 2021-06-09 | F. Hoffmann-La Roche AG | Novel soluble sortase a |
AU2019265699A1 (en) * | 2018-05-08 | 2021-01-07 | Amgen Inc. | Bispecific antibodies with cleavable C-terminal charge-paired tags |
JP7416715B2 (ja) * | 2018-11-07 | 2024-01-17 | 公益財団法人川崎市産業振興財団 | ペプチド-核酸複合体 |
CN110357970A (zh) * | 2019-07-10 | 2019-10-22 | 杭州纽龙日尚生物制品有限公司 | 一种易于纯化的人表皮生长因子融合蛋白及其核酸分子、一种人表皮生长因子制备方法 |
KR20240043837A (ko) * | 2022-09-27 | 2024-04-04 | 크리포 주식회사 | 정제 태그와 알파-나선 태그를 포함하여 자가 조립체를 형성하는 융합 단백질 및 이를 이용하여 재조합 단백질을 정제하는 방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009055837A (ja) * | 2007-08-31 | 2009-03-19 | Shionogi & Co Ltd | タンパク質の固定化方法 |
US20090088372A1 (en) * | 2006-03-22 | 2009-04-02 | National Institute Of Immunology | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
US20070148166A1 (en) * | 2002-05-13 | 2007-06-28 | Wu Madeline C S | Scfvs in photosynthetic microbes |
WO2005051976A2 (en) * | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
US8940501B2 (en) * | 2009-01-30 | 2015-01-27 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
US20120282670A1 (en) * | 2009-11-04 | 2012-11-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for enhancing production of a biological product |
CN103764665A (zh) | 2011-06-28 | 2014-04-30 | 怀特黑德生物医学研究所 | 使用分选酶安装用于蛋白质连接的点击化学柄 |
US10309969B2 (en) * | 2013-01-24 | 2019-06-04 | Abtlas Co., Ltd. | Protein combination-based FV library, and preparation method therefor |
US9631218B2 (en) | 2013-03-15 | 2017-04-25 | The Trustees Of The University Of Pennsylvania | Sortase-mediated protein purification and ligation |
EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
-
2014
- 2014-04-25 US US14/785,881 patent/US10077299B2/en active Active
- 2014-04-25 CA CA2909513A patent/CA2909513C/en not_active Expired - Fee Related
- 2014-04-25 CN CN201480033267.9A patent/CN105339391B/zh active Active
- 2014-04-25 EP EP14787873.0A patent/EP2990423B1/en active Active
- 2014-04-25 AU AU2014258109A patent/AU2014258109B2/en not_active Ceased
- 2014-04-25 WO PCT/KR2014/003639 patent/WO2014175690A1/ko active Application Filing
- 2014-04-25 KR KR1020157030691A patent/KR101808223B1/ko active IP Right Grant
- 2014-04-25 NZ NZ713602A patent/NZ713602A/en not_active IP Right Cessation
- 2014-04-25 RU RU2015150335A patent/RU2639527C2/ru not_active IP Right Cessation
- 2014-04-25 SG SG11201508732PA patent/SG11201508732PA/en unknown
- 2014-04-25 JP JP2016510621A patent/JP6176392B2/ja active Active
-
2015
- 2015-10-18 IL IL242147A patent/IL242147B/en not_active IP Right Cessation
-
2018
- 2018-08-09 US US16/100,080 patent/US20190077846A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090088372A1 (en) * | 2006-03-22 | 2009-04-02 | National Institute Of Immunology | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof |
JP2009055837A (ja) * | 2007-08-31 | 2009-03-19 | Shionogi & Co Ltd | タンパク質の固定化方法 |
Non-Patent Citations (7)
Title |
---|
ANTOS, J. M. ET AL.: "Lipid modification of proteins through sortase-catalyzed transpeptidation.", J. AM. CHEM. SOC., vol. 130, no. 48, 3 December 2008 (2008-12-03), pages 16338 - 16343, XP008152225 * |
ANTOS, J. M. ET AL.: "Site-specific N- and C-terminal labeling of a single polypeptide using sortases of different specifcity.", J. AM. CHEM. SOC., vol. 131, no. 31, 12 August 2009 (2009-08-12), pages 10800 - 10801, XP055070582 * |
DATABASE GENBANK [online] 10 October 2012 (2012-10-10), ILANGOVAN, U. ET AL.: "Structure Of Sortase", XP055288250, retrieved from NCBI Database accession no. 1IJA_A * |
KOBASHIGAWA, Y. ET AL.: "Attachment of an NMR-invisible solubility enhancement tag using a sortase-mediated protein ligation method.", J. BIOMOL. NMR., vol. 43, no. 3, 13 January 2009 (2009-01-13), pages 145 - 150, XP019680283 * |
MAO H ET AL., PROTEIN EXPR. PURIF, vol. 37, no. 1, 2004, pages 253 - 63 |
MAO, H.: "A self-cleavable sortase fusion for one-step purification of free recombinant proteins.", PROTEIN EXPR. PURIF., vol. 37, no. 1, September 2004 (2004-09-01), pages 253 - 263, XP004523963 * |
PROFT, T.: "Sortase-mediated protein ligation: an emerging biotechnology tool for protein modification and immobilisation.", BIOTECHNOL. LETT., vol. 32, no. 1, 1 September 2009 (2009-09-01), pages 1 - 10, XP019766760 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109072212A (zh) * | 2016-03-30 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 改善的分选酶 |
US10900026B2 (en) | 2016-03-30 | 2021-01-26 | Hoffmann-La Roche Inc. | Sortase |
CN109072212B (zh) * | 2016-03-30 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 改善的分选酶 |
US11572552B2 (en) | 2016-03-30 | 2023-02-07 | Hoffmann-La Roche Inc. | Sortase |
Also Published As
Publication number | Publication date |
---|---|
NZ713602A (en) | 2016-09-30 |
US20160137720A1 (en) | 2016-05-19 |
CA2909513C (en) | 2018-10-09 |
US20190077846A1 (en) | 2019-03-14 |
CN105339391A (zh) | 2016-02-17 |
KR101808223B1 (ko) | 2017-12-13 |
RU2015150335A (ru) | 2017-05-31 |
CN105339391B (zh) | 2021-01-01 |
EP2990423B1 (en) | 2018-04-18 |
RU2639527C2 (ru) | 2017-12-21 |
EP2990423A1 (en) | 2016-03-02 |
CA2909513A1 (en) | 2014-10-30 |
AU2014258109B2 (en) | 2016-09-29 |
US10077299B2 (en) | 2018-09-18 |
JP6176392B2 (ja) | 2017-08-09 |
AU2014258109A1 (en) | 2015-11-12 |
EP2990423A4 (en) | 2016-10-26 |
SG11201508732PA (en) | 2015-11-27 |
KR20160007509A (ko) | 2016-01-20 |
JP2016519118A (ja) | 2016-06-30 |
IL242147B (en) | 2019-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014175690A1 (ko) | 자가 절단 카세트를 포함하는 단백질 정제방법 및 이의 용도 | |
AU2014230129B2 (en) | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme | |
KR950000299B1 (ko) | 융합 단백질의 제조방법 | |
EP2075336B1 (en) | Purification of recombinant proteins fused to multiple epitopes | |
Roy et al. | Expressed protein ligation to probe regiospecificity of heterocyclization in the peptide antibiotic microcin B17 | |
Liu et al. | Single-step purification of recombinant proteins using elastin-like peptide-mediated inverse transition cycling and self-processing module from Neisseria meningitides FrpC | |
JPS59162887A (ja) | 生長ホルモン放出因子grfコ−ド構造遺伝子を含有する二本鎖ポリデオキシニユクレオチド | |
KR20210094895A (ko) | 신규 펩타이드 태그, 이에 결합하는 항체 및 이들의 용도 | |
CA3087218C (en) | Biological synthesis of amino acid chains for preparation of peptides and proteins | |
WO2019231208A1 (ko) | 폴리유비퀴틴 링커에 결합된 선형 다기능성 멀티머 생체분자 및 이의 용도 | |
Groothuys et al. | Chemoenzymatic synthesis of triazole-linked glycopeptides | |
WO2014014207A1 (en) | Antibody for epitope tagging, hybridoma cell line and uses thereof | |
WO2020139031A1 (ko) | Crispr-cas를 기반으로 하는 유전자 교정용 조성물 | |
JPH10127295A (ja) | リシントキシン | |
WO2023153761A1 (ko) | 당사슬이 절단된 신규 항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물 | |
WO2024090815A1 (ko) | 식물로부터 인유두종 바이러스 유사 입자의 생산 | |
WO2021125917A1 (ko) | Whep 도메인 융합에 의한 목적 단백질의 수용성 증진 방법 | |
WO2020141930A1 (ko) | 피에이치 의존적 막 투과성 펩타이드를 이용한 약물 운반체 및 그것과 약물의 복합체 | |
WO2021045292A1 (ko) | Crm197 단백질 발현 방법 | |
RU1438240C (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК РТNF 22, СОДЕРЖАЩАЯ ПОЛУСИНТЕТИЧЕСКИЙ ГЕН ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА - ПРОМЕЖУТОЧНАЯ ПЛАЗМИДА ДЛЯ КОНСТРУИРОВАНИЯ РЕКОМБИНАНТНОЙ ПЛАЗМИДНОЙ ДНК pTNF 31, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ ESCHERICHIA COLI - ПРОДУЦЕНТ ПОЛИПЕПТИДА СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА | |
WO2018106000A2 (ko) | 헴중합효소와 헴 라이게이즈를 포함하는 효소복합체 및 이를 이용한 헤모조인의 제조방법 | |
CN115850500A (zh) | 一种抗传染性法氏囊病病毒vp2及鸡cr2的双特异性抗体 | |
Esipov et al. | Recombinant Thymosin α1 | |
Baek et al. | Construction of a new gene-fusion expression vector, pMONSTER | |
KR19980050578A (ko) | 섬자리공 항바이러스성 단백질(pip)의 유전자를 이용한 pcr 클로닝벡터 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480033267.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14787873 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2909513 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 242147 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14785881 Country of ref document: US Ref document number: 2014787873 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157030691 Country of ref document: KR Kind code of ref document: A Ref document number: 2016510621 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014258109 Country of ref document: AU Date of ref document: 20140425 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015150335 Country of ref document: RU Kind code of ref document: A |